190771-02-9Relevant academic research and scientific papers
2-Aryloxy-4-alkylaminopyridines: Discovery of novel corticotropin-releasing factor 1 antagonists
Chen, Yuhpyng L.,Obach, R. Scott,Braselton, John,Corman, Michael L.,Forman, James,Freeman, Jody,Gallaschun, Randall J.,Mansbach, Robert,Schmidt, Anne W.,Sprouse, Jeffrey S.,Tingley III, F. David,Winston, Elizabeth,Schulz, David W.
, p. 1385 - 1392 (2008/09/20)
An orally active clinical candidate of corticotropin-releasing factor 1 (CRF1) antagonist 1 showed a significant positive food effect in dog and human after oral administration. Efforts to address the food effect issue led us to explore and dis
Corticotropin releasing factor antagonists
-
, (2008/06/13)
Corticotropin-releasing factor (CRF) antagonists having the formulae wherein the dashed lines, A, B, Y, Z, G, R3, R4, R5, R6, R16 and R17 are as defined in the application, and processes fo
Method of treating heart failure
-
, (2008/06/13)
This invention relates to method for treating a mammal which presents with heart failure comprising administering to a mammal a therapeutically effective amount of wherein 4-(1-ethyl-propoxy)-3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridine and (3,6-dime
Use of 3,6-dimethyl-2-(2,4,6-trimethylphenoxy)-pyridines for treating heart failure
-
, (2008/06/13)
This invention relates to treatments for a mammal which presents with heart failure comprising administering to a mammal a therapeutically effective amount of wherein 4-(1-ethyl-propoxy)-3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridine and (3,6-dimethyl-
